Violin plot data: A concerto of crucial information on valve thrombogenicity classified using laboratory measured valve motion
Lawrence N. SCOTTEN a, Dipl.T., David BLUNDON b, PhD.,
Marcus-André DEUTSCH c, MD., Rolland SIEGEL d, BA

Affiliations:
a Independent consultant, Victoria, BC, Canada
b Instructor, Environmental Technology Program and Biology Department, Camosun College, Victoria BC, Canada
c Surgeon – Cardiothoracic, Klinik fur Thorax- und Kardiovaskularchirurgie, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany
d Independent consultant, Portland, Oregon, USA

Conflict of interest statement: None declared.

Sources of funding: None declared.

Correspondence: Lawrence N. SCOTTEN, 1560 Bonair Place, Victoria, BC, V8P 4V4, Canada
E-mail: larryscotten2@hotmail.com
Mobile phone number (office and home) 1-250-812-2507

Abbreviations and Acronyms (minimized):
BHV = bioprosthetic heart valve
BV3D = rapid prototype bileaflet mechanical valve (3D printed)
HITS = high intensity transcranial signal
ml/s = milliliters per second
m/s = meters per second
ms = milliseconds
mTAVR = mock-transcatheter aortic valve replacement
MHV = mechanical heart valve
PDVA = projected dynamic valve area
PVL = paravalvular leakage
RFV = regurgitant flow velocity
s = second
SJM = St Jude Medical
TP = thrombogenic potential
VIA = viscoelastic impedance adapter
Central Message (short)  Thrombogenic potential due to blood cell damage by anomalous valve motion and non-physiologic flow dynamics requires design innovation to produce an advanced mechanical valve.

Perspective Statement (short)
Multiple modifications to mechanical and bioprosthetic valves have not resolved chronic shortcomings related to thrombogenicity and durability. New perspectives are required for a development pathway to eliminate thrombogenicity in the former and extend durability in the latter.

Central Picture and Legend
Depiction of prototype mechanical valve.
**Perspective** Nearly 60 years after their introduction, modifications to mechanical and bioprosthetic valves have not yet resolved chronic shortcomings related to durability and thrombogenic potential. In prior publications, we hypothesized that mechanical valve occluder closing behavior was conspicuously implicated in the thrombogenic discrepancy between mechanical and bioprosthetic valves and this was evidenced in laboratory experiments by assessment of valve regional flow velocity. Although computational methods employed to examine contemporary mechanical and bioprosthetic valve function have generated extensive information on device fluid dynamics, a development pathway has not yet been proposed to eliminate thrombogenicity in the former and extend durability in the latter. If our study methods are verifiable, the design of future valves may utilize currently available experimental tools to produce advanced devices with significantly reduced thrombogenic potential.

**Structured Abstract:**

**Objectives:** We hypothesize that prosthetic valve thrombogenic potential may be inferred by valve regional flow velocity. This metric was used to compare two clinical valves and two experimental prototypes.

**Methods:** Four our clinical and experimental prototype valve models were tested in aortic and mitral sites under pulsatile circulation in a pulse duplicator. An optical approach measuring projected dynamic valve area to gauge valve motion was implemented. Pulsatile pressures and flow rates were measured by conventional techniques and a quasi-steady flow tester was used to measure valve leakage. Regurgitant flow velocity was derived using time-dependent volumetric flow rate / projected dynamic valve area. Since flow velocity and fluid shear force are related through flow velocity gradient, thrombogenic potential for valves that achieve near closure during the forward flow deceleration phase were determined as regurgitant flow velocities relative to the control mechanical valve regurgitant flow velocity of -126 m/s. Analysis of the flow velocity data made use of Vioplot R* and VISIO software packages to provide split violin plots that represent probability of recurrence of data.

**Results:** Thrombogenic potential was made dimensionless and ranged between -0.45 and +1.0. Negative thrombogenic potentials arise when transient rebound of valve occluder is accompanied by water-hammer phenomena. Positive thrombogenic potentials occur during decelerating forward flow. Bioprostheses had lowest thrombogenic potential transient of 0.15. A mock-transcatheter aortic valve replacement incorporating by design a trivial paravalvular leak (~1.35 ml/s) demonstrated a high transient thrombogenic potential of 0.95.

**Conclusions:** Our data reveals distinct thrombogenic potential profile differences between valve models. If our study methods are verifiable, the design of future valves may utilize currently available experimental tools to produce advanced devices with significantly reduced thrombogenic potential.
**Graphical Abstract**

![Graphical Abstract Image](image)

**Central Message** Valve motion and flow velocity contribute to valve thrombogenic potential (TP) as revealed by closure-related functional deficit common to current mechanical heart valves (MHVs). Appreciation of valve closure is crucial to design of advanced valves with TP comparable to tissue valves and is achievable with current technology. Consistent with recent clinical experience, data from our mock transcatheter aortic valve replacement (mTAVR) device suggests modifications to commercial TAVR prostheses to reduce PVL results in smaller paravalvular leaks (PVLs) with greater TP. A consequential outcome of our work is development of a practical laboratory method for screening prototype valves for TP compared with well established clinical controls.

**Perspective** Nearly 60 years after their introduction, modifications to mechanical and bioprosthetic valves have not yet resolved chronic shortcomings related to durability and thrombogenic potential. In prior publications, we hypothesized that mechanical valve occluder closing behavior was conspicuously implicated in the thrombogenic discrepancy between mechanical and bioprosthetic valves and this was evidenced in laboratory experiments by assessment of valve flow velocity. Although computational methods employed to examine contemporary mechanical and bioprosthetic valve function have generated extensive information on device fluid dynamics, a development pathway has not yet been proposed to eliminate thrombogenicity in the former and extend durability in the latter. If our study methods are verifiable, the design of future valves may utilize currently available experimental tools to produce advanced devices with significantly reduced thrombogenic potential.
I. Introduction and Background

Nearly 60 years after their introduction, modifications to mechanical and bioprosthetic valves have not yet resolved chronic shortcomings related to durability and thrombogenic potential. Early published data on sources of thrombogenicity in mechanical valves by Davey [1] in 1966, visualized cyclic flow behavior by high-speed cinematography in a pulse duplicator with a transparent chamber and a sheet of light flow technique using aluminum flow tracer particles in transparent test fluids. Flow patterns, adjacent to an early model Starr-Edwards valve ball-occluder, were identified and multiple retrograde impulses were observed at valve closure. Although the investigators speculated that these events were associated with high shear, equipment of that era was incapable of measuring the retrograde flow velocities associated with occluder rebound phenomena [Davey, TB]. More recently, computational methods employed to examine flow patterns, flow velocities, and pressures associated with contemporary mechanical and bioprosthetic valve function have generated extensive information on flow but as yet have not proposed a development pathway to eliminate thrombogenicity in the former and extend durability in the latter [e.g. 2-4].

In prior publications, [5-9] we hypothesized that mechanical valve occluder closing behavior was implicated in the thrombogenic discrepancy between mechanical and bioprosthetic valves. Our modified pulse duplicator allowed measurement of prosthetic valve dynamic area (PDVA) providing crucial insight into occluder forward flow flutter, cavitation and occluder rebound that contribute to the complex genesis of valve thrombosis. Subsequent pulse duplicator adaptations included a unique electro-optical subsystem referred to as Leonardo [6] that revealed spatially averaged flow velocity in immediate proximity to test valves. We found that, transient regurgitant flow velocities (RFVs), occurred often near MHV closure, and proposed it as a proxy [6-9] for rapidly changing shear forces. Shear forces are known to promote formation of micro-thrombi aggregates that may remain locally adherent or embolize. This work provided incentive to refine geometry of a mechanical heart valve (MHV) with blood damage potential reduced to tissue valve levels. Included in these investigations were modified bileaflet [7] and trileaflet designs [6, 10, 11]. Also, this experimental methodology was extended to study thrombogenic potential in transcatheter aortic valve replacement (TAVR) devices [8, 9].

II. Methods

A) Test Apparatus

An extensively cited commercial in vitro test system [3, 5-9] was used with typical simulation conditions including pulse rate 70 cycles/min; pressures ca.120/80 mmHg (millimeters of mercury); and cardiac output 5 litres/min. Basic test methodology is depicted in Figure 1. Test valves included: a CLINICAL MECHANICAL (SJM, St Jude Medical Regent™; Abbott Laboratories, Abbott Park, Ill, USA); a RAPID PROTOTYPE MECHANICAL (BV3D) [7]; a CONTROL BIOPROSTHESIS Carpentier-Edwards Perimount (Edwards Lifesciences, Irvine,
CA, USA) and a MOCK-TAVR construct fabricated using a bovine pericardial aortic valve Carpentier-Edwards Perimount mounted in a purpose-built fixture [8].

![Diagram](image)

**Figure 1**: Basic test methodology uses optical approach to gauge aortic and mitral prosthetic heart valve motion quantified as projected dynamic valve area (PDVA).

Nominal valve sizes were 25 mm tissue annulus diameter (TAD). Valves tested in pulsatile and quasi-steady pressure/flow systems and PDVA in pulsatile flow was obtained. Time-dependent inferred RFV was derived by dividing the volumetric flow rate by the PDVA (volumetric flow rate/PDVA). A separate leakage tester (ViVitro Labs Inc., model LT8991, circa 1998) provided accurate measurements of small closed valve leakage rates, under quasi-steady gravity head generated pressure/flow conditions. Such measures were used to estimate aggregate valve leakage area described previously [8].
The Leonardo modified pulse duplicator originally adapted in 2011 with innovative features to measure PDVA from backlit valves remains in current use with improved spatial and temporal resolution capability (i.e., 0.001 centimeter$^2$ and 1 microsecond). Valves tested in this system were recently compared to numerical simulations for contemporary porcine tissue and bovine pericardial bioprosthetic heart-valves and also with data from a similar independent pulse duplicator with excellent conformity [3].

A visco-elastic impedance adapter (VIA) models bulk ventricular visco-elasticity to produce physiological isovolumetric functionality has been utilized in several previous studies [3, 6-10]. Jennings et al. [13] in their use of the Leeds in vitro valve tester to study stentless porcine valves found VIA advantageous in ameliorating unphysiological left-ventricular pressure oscillations. Ventricular visco-elasticity associates with valve opening and closure dynamics, ventricular pressure rates ($dp/dt$), propensity for microbubbles, high intensity trancranial signals (HITS), cavitation, acoustic emissions, and vortex flow formations. Recently, Lee et al. [3] characterized VIA as a three-element Windkessel and utilized in fluid-structure interaction models of bioprosthetic heart valve dynamics. These models were validated with an experimental pulse duplicator.

As previously described, closed valve leakage was accurately measured in a quasi-steady pressure/flow apparatus calibrated with known small orifice areas [6-9]. Total valve leakage area was then edited into the experimental data and subsequently analyzed (leakage areas: SJM=0.0178 centimeter$^2$; BV3D=0.003 centimeter$^2$; Edwards Perimount$^{TM}$ Bioprosthesis=0.012 centimeter$^2$).

B) Leonardo
Since only fleeting glimpses of prosthetic valve motion can be seen by the unaided eye, we developed a simple technique to quantify high-speed valve motion detail (Basic Leonardo, Figure 1). Described previously, this approach provides important analog data about valve motion [3, 5-11]. Technical specifications for the current Leonardo sub-system [7] include:

- Temporal resolution (based on voltage step waveform response, rise time from 10% to 90% amplitude) ≈1.04 μs;
- Bandwidth ≈ 0.35/risetime = 0.35/1.04μs = 337 KHz;
- Spatial area resolution (closed valve), 0.001 cm$^2$ (n=10 cycle average);
- Telecentric lens maintains constant magnification ≈0.16 x;
- Working distance ≈18 cm (AORTIC); ≈19 cm (MITRAL);
- Perspective error <0.3% (depth 15 mm);
- Spatial sensitivity variation <6%;
- Typical site dependent linear regression calibrations are:
  - y=0.00128x, with $R^2=0.99988$ (AORTIC);
  - y=0.00132x, with $R^2=0.99959$ (MITRAL);
- LED back light source (diffuse red):
C) Violin Plots with Relative Flow Velocity Scaling

Although Violin Plots were not previously utilized for visualization of in-vitro valve test results, they attracted our attention as a powerful synergistic technique, introduced in 1998 by Hinze and Nelsen [12], to present voluminous quantitative or qualitative datasets. The violin plot is the union of density shape, kernel density estimate, and summary statistics relevant to boxplots. Figure 2 depicts TP probability density near valve closure and reveals different peaks, their position, and relative amplitudes. Readers will appreciate that broader split-violin regions convey more probable flow velocities than those in narrower regions. TPs for valves during the decelerating forward flow phase on the verge of closure were determined as RFVs relative to a control mechanical valve RFV value of -126 m/s. RFV was derived using time-dependent volumetric flow rate/PDVA.

![Diagram of Violin Plots](image_url)

**Figure 2:** Sample split violin-plot depiction of inferred dimensionless valve thrombogenic potential (TP). Shaded profiles represent probability of recurrence of TP relative to RFV of -126 m/s. Full violin plots are symmetric and can be split, without loss of information, with each configuration representing independent data (n=150). Minimum X data values comprise those with minimum probability of recurrence but exhibit largest TP magnitudes.
Figure 3: Dimensionless thrombogenic potential (TP) of valves (based on near closure RFV relative to -126 m/s). Early prototype valve rapid printed prototype bileaflet mechanical valve (BV3D) is shown in full open and closed views; Negative TPs involve water hammer and occluder rebound phenomena except for valve BV3D where further development is pending. Vioplot R software analyzed a 10,500 dataset to create full-violin plots and Visio** software facilitated the split-violin graphics shown.

Figure 3 shows SJM and mTAVR are more similar, in the aortic position, with maximum TPs at or near 1.0. The rapid prototype BV3D and Edwards-Pericardial (control tissue valve) are more similar with maximum TPs near 0.25.
D) Regurgitant Flow Velocity and Shear Force
Regurgitant flow velocity (RFV) magnitudes shown in Figure 3 can be considered a shear force surrogate associated with valve TP. Since flow velocity and fluid shear are related through flow velocity gradient, a proxy for valve thrombogenic potential may be inferred by flow velocity. Valve RFV is equal to volumetric flow rate, divided by the PDVA (flow rate/PDVA) and is an estimate of the regional instantaneous spatial average.

Although TP cannot be assumed to increase linearly with flow velocity it is considered proportional to the inferred regional flow velocity (m/s) and independent of valve fabrication materials. The regional flow velocity determined by Leonardo is an estimated spatial average quantity (m/s) and not a site specific quantity. Since flow velocity gradients cannot be obtained with Leonardo, neither can shear force per unit area values (dyne/centimeter$^2$) from measured RBVs (m/s).

E) Derivations and PDVA Synchronization Adjustment
Analog signal bandwidth differences between PDVA and transvalvular volumetric flow rate were 0-337 KHz vs. 0-100 Hz, respectively. The PDVA signal preceded the other signals by -2.5 ms based on step signal response thus a phase adjustment between the PDVA and the other signals was required. Accordingly, post experiment, we shifted the acquired PDVA signal 1 data acquisition interval of -3.4 ms [6].

F) Violin Plots with Relative Flow Velocity Scaling
Over time, as alternate TP assessment metrics evolved, valve thrombogenic potential appears to remain consistent by multiple determinations (Table 1). For example, a widely used clinical MHV (SJM, St Jude Medical) has consistently exhibited high TP compared with controls regardless of determination method [6-10]. In all examples, determinations utilized valve motion as a component metric for obtaining TP [6-10].

Vioplot R* software package and Visio 2002 ** have been utilized to create the split-violin plots used in this study. *R Core Team (2019) R: A Language and environment for statistical computing. R Foundation for Statistical computing, Vienna, Austria, URL https://www.R-project.org
** Microsoft, Redmond, WA, USA
TABLE 1: Determination of TP for SJM aortic test valve -example

| Thrombogenic Potential (TP)                      | Quantity | References |
|-------------------------------------------------|----------|------------|
| Peak Backflow Velocity, meters/second           | -235     | 6          |
| Thrombogenic Potential Index (TPI)              | 3.9      | 7          |
| Split violin, maximum TP                        | 1.0      | (Present study) |

The photograph in Figure 4 is from our 2011 publication [6] which captures saline jetting through small clearances intrinsic to a closed SJM aortic valve driven by a transvalvular back pressure of 120 mmHg.

Complex geometric gaps are present in all current mechanical valve designs. The total aggregate gap area for the closed SJM valve in Figure 4 is 0.0178 centimeter$^2$ and under pulsatile flow conditions has a maximum spatially averaged regional flow velocity of ~126 m/s near valve closure.

Figure 4: Photograph of multiple intra-valvular saline leakage jets passing through a closed St Jude Medical (SJM) mechanical valve. Transvalvular backpressure on closed valve is ca. 120 mmHg. Photo details: Camera SONY model DSC-T100, f/4.4, exposure time 1/50 s, and flash mode enabled.

Readers are familiar with the qualitative echocardiographic signature of these retrograde jets during immediate post implant assessment of mechanical valves to detect peri-prosthetic leak; however, the magnitude and short duration of these flow transients cannot be resolved. In the absence of clinically significant hemolysis, thrombotic obstruction or thromboembolic events,
the longer term implications of the conspicuous retrograde velocities, for recipient coagulation system-components, have remained largely unknown.

Recent clinical findings, that paravalvular leaks (PVL) are common (~33%) after TAVR [14] identify micro-jets as a cause for hemolysis with thrombogenic consequences now evolving [15, 16]. Interestingly, lactate dehydrogenase (LDH) values have been largely ignored until recently when a reduction of 600 U/L was reported and considered significant [15]. LDH activity is expressed in U/L (International units) defined as the amount of enzyme that catalyzes the conversion of 1 micro-mol of substrate per minute under specified conditions. Evidence is emerging that the smaller the PVL, the higher the TP [8, 17].

PVL closure may have a therapeutic effect on the extent of hemolysis that some patients experience after valve surgery. Reduction of hemolysis is most likely in a patient with a mechanical valve and is not necessarily correlated with the volume of regurgitant flow or its subsequent reduction. Hemolysis associated with biological valves are less likely to respond to PVL closure suggesting that mechanisms other than net volume of regurgitation or micro-jets are present and should be considered [14, 15].

III. Results and Discussion

At near valve closure, flow dynamics can be considered analogous to transient valve stenosis, whereby regurgitation is increasingly constrained until complete, motionless, closed-valve conditions occur. During brief crucial moments preceding valve closure, localized prothrombotic microenvironments may be relevant to generation of high velocity leakage jets, flow unsteadiness, valve flutter, cyclic variability of PDVA, turbulence, and excessive shear forces that may induce blood element damage [15-31]. These influences may impact multiple valve types for:

- conduction abnormalities,
- reduced valve leaflet mobility, sub-clinical thrombosis [17, 23, 26-28, 30],
- potential for pannus formation,
- silent cerebral micro-infarction [24, 25],
- acute and sub-acute embolic stroke and other adverse cerebrovascular events including TIA [24, 26],
- cavitation and high intensity trans-cranial signals (HITS) [6].

Closure dynamics therefore may be directly related and analogous to:

1. Pro-thrombotic aspects of valve forward flow (e.g., valve stenosis) and arterial flows (e.g., arterial sclerosis).
2. Biomechanical and biochemical responses sufficient to exacerbate risk for pathologic thrombus formation and propagation.
3. Rebound and water-hammer for the SJM valve in the mitral position consistently manifested leaflet rebound observed as a momentary post closure partial re-opening driven by water-hammer power (transvalvular pressure × volumetric flow rate). This has been previously reported with magnified examples of high-resolution PDVA rebound data [7].

4. The SJM valve produces water-hammer with a maximum approaching -0.5; however, the mock-TAVR and Edwards-Pericardial do not. The highest probability of detection is as expected near 0.0 when bioprosthetic valves arrive at closure.

Figure 3 compares several contemporary and prototype cardiac valves near closure extending over ~495 ms. One hundred fifty (150) RFV data points were accumulated for each valve over 10 consecutive cycles. The time increment was ~3.4 ms which was the interval used to collect data over the total cycle time of 867 ms (cycle rate = 70 per minute). Inferred dimensionless TP of the test valves (Y axis) is referenced to an RFV of 126 m/s, the peak observed for the SJM MHV.

A) Study outcomes (previous and present reports) [6-10]:

1. High amplitude RFVs and resultant supra-physiologic shear forces originating in small intra- and PVL gaps are mechanistic initiators of the clotting cascade.
2. Platelet activation is induced by high shear even with short exposure time [19, 20].
3. Closing dynamics disparity between MHV and bioprosthetic valves is chronically overlooked as a primary indicator of valve TP.
4. Current MHVs have overt RFV transients at closure relating to occluder non-response to flow deceleration and residual PDVA.
5. A mock-TAVR valve with trivial PVL generated high amplitude short duration RFVs.
6. For a given volumetric backflow rate near valve closure, the smaller the total residual leakage area, the greater the RFV magnitude.
7. The highest recorded RFVs were generated by the SJM valve compared to the tissue control valves (Edwards pericardial).
8. A spatial average of RFVs in immediate proximity to prototype valves may be a practical indicator in qualitative screening for valve TP.
9. Valve BV3D test data suggest that specific MHV leaflet geometries generate a closure force, during forward flow deceleration and prior to flow reversal, a potentially beneficial “soft closure” response.
10. Our results infer shear damage to formed blood elements and a resultant continuous thrombogenic response. This constitutes a mechanistic explanation for observed thrombogenic disparity, in prosthetic valve types and designs, now broadened to include observations of TAVR related thromboembolic events.
11. For MHVs, cyclic RFVs appear to be related to a prothrombotic state requiring chronic anticoagulation.
12. Bioprosthetic valves appear not to generate a pro-thrombotic closing phase; however, TAVR prostheses with trivial PVL may have pathologic RFVs similar to those observed in MHVs [8].

B) Caveats
Valve regional flow velocities are useful surrogates for flow induced blood cell damage potential; however, TP cannot be directly inferred from derived maximum flow velocities, considering the complexity of blood coagulation factors, recently reviewed by Rana and associates [21]. For example, the difference between laminar and turbulent flow, and their respective impact on blood component damage, awaits experimental evidence to validate numerical simulations [22]. In contrast to laminar flow, turbulent fluid flow is characterized by chaotic flow/pressure fluctuations with sufficient shear force to activate blood clotting mechanisms and influence von Willebrand factor (vWF) mechanisms [31].

IV. Conclusions
Our prior work found valve motion and flow velocity constitute a primary contribution to valve TP and that closure-related functional deficit is a common shortcoming of current MHVs [6-9]. Progress, beyond the limitations of current prosthetic valves, requires appreciation of valve closure as a crucial factor. Very high-flow velocity short-duration RFVs near valve closure (Figure 4) result in transient blood cell damage each cardiac cycle and initiation of the coagulation cascade [20, 21]. Additionally, results suggest that designing a MHV with reduced TP, comparable to clinically well established tissue valves, is achievable with current technology. On a cautionary note, device manufacturers preoccupied with modifications of catheter delivered valves, to minimize residual leak, assume that a minor (trivial) leak reduces patient risk. However, we consistently observe smaller volume metric PVLs associate with higher magnitude RFVs and conversely; larger PVLs result in lower RFVs and shear forces. This is consistent with recently reported clinical experience where independent predictors of late leaflet thrombosis, up to 3 years post implant, were male sex and PVL less than mild [17].

Footnotes
Contributions: (I) Conception and design: LN Scotten; (II) Administrative support: LN Scotten; (III) Provision of study materials: LN Scotten; (IV) Collection and assembly of data: LN Scotten; (V) Data analysis and interpretation: LN Scotten, D Blundon; (VI) Manuscript writing: All authors; (VII) All authors have approved the final submitted version of the manuscript.
Acknowledgements: Jason Nicholls utilized SolidWorks software for modeling and Keyshot software for rendering the valve prototype BV3D in central picture and Figure 3. Provenance and peer review: Not commissioned; externally peer reviewed

Financial Disclosure: This research has been done on a pro bono basis by all authors with no financial support of others.

Data sharing statement: All data relevant to the study are included in the article.

Open access statement if applicable: Anyone can share, reuse, remix, or adapt this material, providing this is not done for commercial purposes and the original authors are credited and cited.

V. References

[1] Davey TB, Kaufman B, Smeloff, EA. Pulsatile flow studies of prosthetic heart valves. J Thorac Cardiovasc Surg 1966;51:264-7. Google Scholar

[2] Bluestein D, Chandran KB, Manning KB. Towards non-thrombogenic performance of blood recirculating devices. Ann Biomed Eng 2010;38:1236-56. PubMed Abstract | Google Scholar

[3] Lee JH, Rygg AD, Kolahdouz EM, Rossi S, Retta SM, Duraiswamy N, et al. Fluid-structure interaction models of bioprosthetic heart valve dynamics in an experimental pulse duplicator. Ann Biomed Eng 2020;7 Feb 2020 https://doi.org/10.1007/s10439-020-02466-4

[4] Consolo F, Sheriff J, Gorla S, Magri N, Bluestein D, Pappalardo F. High frequency components of hemodynamic shear stress profiles are a major determinant of shear-mediated platelet activation in therapeutic blood recirculating devices. Sci Rep 2017;7:4994-5008. PubMed Abstract | Google Scholar

[5] Scotten LN, Walker DK. New laboratory technique measures projected dynamic area of prosthetic heart valves. J Heart Valve Dis 2004;13:120-32; discussion 132-3. PubMed Abstract | Google Scholar

[6] Scotten LN, Siegel R. Importance of shear in prosthetic valve closure dynamics. J Heart Valve Dis 2011;20:664-72. PubMed Abstract | Google Scholar

[7] Scotten LN, Siegel R. Are anticoagulant independent mechanical valves within reach –fast prototype fabrication and in-vitro testing of innovative bi-leaflet valve models. Ann Transl Med 2015;3:197-205. PubMed Abstract | Google Scholar

[8] Scotten LN, Siegel R. Thrombogenic potential of transcatheter aortic valve implantation with trivial paravalvular leakage. Ann Transl Med 2014;2:43. PubMed Abstract | Google Scholar

[9] Chaux A, Grey RJ, Stuoka JC, Emkin MR, Scotten LN, Siegel R. Anticoagulant independent mechanical heart valves –viable now or still a distant holy grail. Ann Transl Med 2016;4:525-601. PubMed Abstract | Google Scholar

[10] Scotten LN, Walker DK, Harbott P, de Hart J, Perrault R, Coisne D, et al. The mechanical Bioprosthesis -does valve motion predict thrombogenicity. Abstract #599, Presentation 16th WSCTS, Ottawa, Canada, 17-20 August 2006.
[11] Carrel T, Dembitsky WP, de Mol B, Obrist D, Dreyfus G, Meuris B, et al. Non-physiologic closing of bi-leaflet mechanical heart prostheses requires a new tri-leaflet valve design. Int J Cardiol 2020. 
https://www.sciencedirect.com/science/article/pii/S0167527319358450

[12] Hinze JL, Nelsen, RD. Violin plots a box plot-density trace synergism. Am Statistician 1998;52:181-184. PDF

[13] Jennings L, Butterfield M, Walker PG, Watterson KG, Fisher J. The influence of ventricular impedance on the hydrodynamic performance of bioprosthetic aortic roots in vitro. J Heart Valve Dis 2001;10:269-275 PubMed Abstract | Google Scholar

[14] Tang GHL, Zaid S, Schnittman SR, Ahmad H, Kaple R, Undemir C, et al. Novel predictors of mild paravalvular aortic regurgitation in SAPIEN 3 transcatheter aortic valve implantation. EuroIntervention 2018;14;58-68.

[15] Gilchrist IC. Treating hemolysis due to paravalvular leaks: It is all about modifying micro-jets and not the volume of regurgitation. Catheter Cardiovasc Interv 2019;93:720-721. PubMed Abstract | Google Scholar

[16] Panaich SS, Maor E, Reddy G, Raphael CE, Cabalka A, Hagler DJ, et al. Effect of percutaneous paravalvular leak closure on hemolysis. Catheter Cardiovasc Interv 2019;93:713-719. https://doi.org/10.1002/ccd.27917 PubMed Abstract | Google Scholar

[17] Yanagisawa R, Tanaka M, Yashima F, Arai T, Jinzaki M, Shimizu H, et al. Early and late leaflet thrombosis after transcatheter aortic valve replacements a multicenter initiative from the OCEAN-TAVI registry. Circ Cardiovasc Interv 2019;12:e007349. doi: 10.1161/CIRCINTERVENTIONS.118.007349 PubMed Abstract | Google Scholar

[18] Hatoum H, Yousefi A, Lilly S, Maureira P, Crestanello J, Dasi LP. An in vitro evaluation of turbulence after transcatheter aortic valve implantation. J Thorac Cardivasc Surg 2018;156:1837-1848. PubMed Abstract | Google Scholar

[19] Ding J, Chen Z, Niu S. Quantification of shear-induced platelet activation: High shear stresses for short exposure time. Artificial Organs 2015;39:576-83. PubMed Abstract | Google Scholar

[20] Soares JS, Sheriff J, Bluestein D. A novel mathematical model of activation and sensitization of platelets subjected to dynamic stress histories. Biomech Model Mechanobiol 2013;12:1127-41. doi: 10.3389/fcvm.2019.00141 PubMed Abstract | Google Scholar

[21] Rana A, Westein E, Niego B, Hagemeyer CE. Shear-dependent platelet aggregation: mechanisms and therapeutic opportunities. Front Cardiovasc Med 2019;6:141-162. doi: 10.3389/fcvm.2019.00141 PubMed Abstract | Google Scholar

[22] Faghih MM, Sharp MK. Modeling and prediction of flow-induced hemolysis: a review. Biomechanics and Modeling in Mechanobiol 2019;18:845–881. doi: 10.3389/fcvm.2019.00141 PubMed Abstract | Google Scholar

[23] Rosseel L, De Backer O, Søndergaard L. Clinical valve thrombosis and subclinical leaflet thrombosis following transcatheter aortic valve replacement: Is there a need for a patient-
[24] Armijo G, Nombela-Franco L, Tirado-Conte G. Cerebrovascular events after transcatheter aortic valve implantation. Front Cardiovasc Med 2018;5:104-118. doi: 10.3389/fcvm.2018.00104. PubMed Abstract | Google Scholar

[25] Musa TA, Uddin A, Loveday C, Dobson LE, Igra M, Richards F, et al. Silent cerebral infarction and cognitive function following TAVI: an observational two-centre UK comparison of the first-generation CoreValve and second-generation Lotus valve. BMJ Open 2019;9:e022329 doi:10.1136/bmjopen-2018-022329 PubMed Abstract | Google Scholar

[26] Rashid HN, Gooley RP, Nerlekar N, Ihdayhid AR, McCormick LM, Nasis A, et al. Bioprosthetic aortic valve leaflet thrombosis detected by multidetector computed tomography is associated with adverse cerebrovascular events: a meta-analysis of observational studies. EuroIntervention 2018; 13:e1748-55. PubMed Abstract | Google Scholar

[27] Deutsch MA, Scotten LN, Siegel R, Lange R, Bleiziffer S. Leaflet thrombosis and clinical events after TAVR: are paravalvular leaks a crucial trigger? EuroIntervention 2018;14:716-717. PubMed Abstract | Google Scholar

[28] Khodaee F, Barakat M, Abbasi M, Dvir D, Azadani AN. Incomplete expansion of transcatheter aortic valves is associated with propensity for valve thrombosis InteractCardioVasc Thorac Surg 2019; doi:10.1093/icvts/ivz213. PubMed Abstract | Google Scholar

[29] Aimo A, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoagulants for mechanical heart valves, is the door still open? Circulation 2018;138:1356-1365. PubMed Abstract | Google Scholar

[30] Themudo R, Kastengren M, Broloin EB, Cederlund K, Svensson A, Dalen M. Leaflet thickening and stent geometry in sutureless bioprosthetic aortic valves. Heart Vessels 2020 doi:10.1007/s00380-020-01553-9 PubMed Abstract | Google Scholar

[31] Van Belle E, Vincent F, Rauch A, Casari C, Jeanpierre E, Loobuyck V et al. von Willebrand factor and management of heart valve disease. J Am Coll Cardiol 2019;73:1078-1088. PubMed Abstract | Google Scholar